AstraZeneca (AZN) Withdraws App for Ovarian-Cancer Treatment in Europe
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
AstraZeneca (NYSE: AZN) is said to have withdrawn its application for approval of cediranib in Europe following a disagreement with regulators.
Bloomberg noted that the action won't affect development of the ovarian cancer treatment.
AstraZeneca filed an application with the European Medicines Agency in June 2015 seeking approval of cediranib for use with platinum-based chemotherapy in adults with a type of ovarian cancer that’s relapsed.
Shares of AstraZeneca are indicated lower Wednesday morning.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Allergan to Present New Data from its Anti-Infectives Portfolio at IDWeek 2016 in New Orleans
- AT&T (T) volatility up into buyout of Time Warner (TWX)
- Stocks with call price movement; LC TWTR
Create E-mail Alert Related CategoriesFDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!